id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1997-N-0059-0001,FDA,FDA-1997-N-0059,Policy on Period of Marketing Exclusivity for Newly Approved Drug Products With Enantiomer Active Ingredients; Request for Comments,Notice,General Notice,1997-01-10T00:00:00Z,1997,1,1997-01-15T05:00:00Z,1997-03-18T04:59:59Z,2025-05-13T20:09:52Z,97-944,0,0,09000064805d02af